Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

may participate in the conference call by dialing (866) 578-5788 or (617) 213-8057, passcode 49255440. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 47807048.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates a
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PLEASANTON, Calif. , Nov. 26, 2014  Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in two upcoming investor conferences. On ... 26 th Annual Piper Jaffray Healthcare Conference.  ... will provide an update on the company beginning at ...
(Date:11/26/2014)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... Products®," today announced the closing of Perrigo,s previously announced ... ordinary shares at a public offering price of $152.00 ... to purchase up to an additional 888,157 ordinary shares ... as representatives of the several underwriters. ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... announced that it has filed a lawsuit in the Netherlands ... Labem, Czech Republic, where Dr. Cervinka is head of the ... conducted at the Masaryk Hospital, in which Dr. Cervinka was ... stent with a bare metal stent for treatment of a ...
... CSL Behring today announced the development ... absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin ... high degree of accuracy and precision. The new PK ... by which SC IgG is transported after it is ...
Cached Medicine Technology:OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation 2OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation 3New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 2New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 3New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 4New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 5New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies 6
(Date:11/28/2014)... November 29, 2014 TideStore.com , has ... new dresses, shoes and other fashion items recently. Its 2014 ... site. , The special offer is valid during Nov. ... tops, stylish women outwears, charming dresses, shining prom shoes, essential ... leading online store offering many trendy clothes and fashion accessories. ...
(Date:11/28/2014)... 2014 The report “Poxvirus Infections ... the therapeutic development for Poxvirus Infections, complete with ... drug target, mechanism of action (MoA), route of ... updates, and featured news and press releases. It ... development for Poxvirus Infections and special features on ...
(Date:11/28/2014)... sells cheap tall cocktail dresses worldwide and ... there is a new collection of tall cocktail dresses ... at very low prices. It is really worthy to ... by UWDress.com , UWDress.com is one of the most ... has the power to ensure customer satisfaction. Now, the ...
(Date:11/28/2014)... 29, 2014 Angelweddingdress.com, a world-famous ... collection of Blue Color Styles of ... up to 80% off and free shipping on ... discounted blue bridesmaid dresses for less at the ... Angelweddingdress.com is famous as a reliable dress supplier ...
(Date:11/28/2014)... New York, NY (PRWEB) November 28, 2014 ... ground-breaking physical therapy techniques such as Dynamic Neuromuscular ... therapy, and gait/motion analysis. After moving to upgraded ... sports and running clinic. Now, owner Dr. Lev ... movement performance and injury prevention lab in the ...
Breaking Medicine News(10 mins):Health News:2014 Special Monday Sales from TideStore.com 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:Graceful Tall Cocktail Dresses With New Features Just Added To UWDress.com 2Health News:Blue Color Styles of Bridesmaid Dresses from AngelWeddingDress.com are Available Now With Big Discounts 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3
... ANN ARBOR, Mich. -- Only about one in five young ... the 2009-2010 swine flu epidemic, according to a University of ... X. But about 65 percent were at least moderately ... were following the issue very or moderately closely. Using ...
... Marriage offers few well-being advantages compared to living together, a ... benefits of marriage diminish over time, while unmarried couples who ... data from 2,737 single men and women who took part ... those people, 896 married or moved in with a partner ...
... Reporter , MONDAY, Jan. 23 (HealthDay News) -- Shedding some light ... finds that parts of your immune system ramp up when you ... this effect of stress may make you sick, but the activated ... body -- have been linked to conditions such as diabetes and ...
... MONDAY, Jan. 23 (HealthDay News) -- Although many people believe ... the opposite may be true with traumatic brain injuries. ... injury in children as young as 2 years, and found ... for some time. However, the researchers also found that recovery ...
... more than 40 years, scientists and physicians have thought eating ... disease of the large intestine in which pouches develop in ... people reveals the opposite may be true. The study, ... Chapel Hill School of Medicine , found that consuming a ...
... A new study published online today in the ... finds hospitals participating in a regional collaborative of the ... (ACS NSQIP), achieved substantial improvements in surgical outcomes, such ... surgical site infections. The collaborative also saved $2,197,543 per ...
Cached Medicine News:Health News:Generation X: How young adults deal with influenza 2Health News:Living Together May Be Mentally Healthier Than Marriage: Study 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 4Health News:Diets high in fiber won't protect against diverticulosis 2Health News:Regional surgical quality collaborative significantly improves surgical outcomes and reduces cost 2Health News:Regional surgical quality collaborative significantly improves surgical outcomes and reduces cost 3
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: